Levodopa Changes Functional Connectivity Patterns in Subregions of the Primary Motor Cortex in Patients with Parkinson’s Disease
Objective: To investigated functional connectivity pattern changes in M1 subregions and relationships to improved clinical symptoms following levodopa administration. Background: The primary motor cortex (M1)…The role of dopamine mis-metabolism in preclinical Parkinson’s disease olfactory deficits
Objective: To gain an understanding of the underlying pathological mechanisms of Parkinson’s disease (PD)-related hyposmia using post-mortem human olfactory bulbs and an in vivo model…Characterization of striatal dopaminergic neurotransmission in the rat pre-formed fibril models of Parkinson’s disease
Objective: To determine the longitudinal effects of synucleinopathy and synucleinopathy-triggered nigrostriatal degeneration on basal and evoked striatal dopamine (DA) release in the striatum at 4…Increased risk of Parkinson’s disease in patients with schizophrenia spectrum disorders
Objective: To investigate the coincidence of Parkinson’s disease (PD) and schizophrenia spectrum disorders (SCD). Background: PD is characterized by a progressive loss of mesostriatal dopamine…Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson’s disease
Objective: To present preliminary 3-year data from the PD-1101 trial of VY-AADC01 for advanced Parkinson’s disease (PD) with motor fluctuations. Background: This 3-year phase 1b…AADC gene therapy administered via a posterior approach: 18-month results from the PD-1102 trial in advanced Parkinson’s disease
Objective: To report 18-month safety and clinical outcomes from a phase 1, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor fluctuations.…A Case of Improved Psychotic Depression and Motor Symptoms in Parkinson’s Disease following Electroconvulsive Therapy (ECT)
Objective: To describe a case of motoric, affective, and psychotic symptoms improving in PD following ECT. Background: Parkinson’s disease (PD) is a neurodegenerative disease caused…Impedance Doesn’t Change with Levodopa Treatment
Objective: We aimed to evaluate the impedance of patients on their best ON/worst OFFs with levodopa, assuming that the level of dopamine at electrode’s vicinity…Preclinical pharmacology and early clinical development of dopamine D1 positive allosteric modulators (D1PAMs) with therapeutic potential for neuropsychiatric disorders
Objective: The objective was to characterize novel dopamine D1PAMs pre-clinically in behavioral and neurochemical models and in phase 1 human studies in healthy volunteers and…How Parkinson’s Disease Affects Working Memory
Objective: Our study designed to (1) measure working memory via verbal Digit Span in Parkinson’s patients without mild cognitive impairment (MCI) (2) determine how dopaminergic…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 24
- Next Page »